share on
Backed by strong clinical, regulatory and research networks, Singapore continues to attract global medtech multinationals seeking to tap Asia Pacific innovation and scale solutions for global healthcare markets, said Cindy Koh, Executive Vice President, Advanced Manufacturing, at EDB.
Asia Pacific’s medtech sector is entering a new phase of growth, shaped by some of the most urgent healthcare challenges facing the region: ageing populations, a rising chronic disease burden and severe healthcare workforce shortages.
Hospitals and providers are being asked to deliver more care to more patients with fewer resources. That is increasing demand for medical technologies that can improve productivity, support earlier diagnosis, expand access to care and deliver better clinical outcomes at lower total cost.
These pressures are also reshaping Asia Pacific’s role in the global medtech industry. For years, Asia Pacific’s role in medtech was largely defined by manufacturing excellence, cost efficiency and the localisation of global innovations. Today, it is increasingly becoming a source of medtech innovation in its own right, with companies creating, validating and exporting globally competitive products.
A new report by Bain & Company, Building Global Champions: The Asia Pacific Region’s Next Medtech Wave, developed in partnership with the Agency for Science, Technology and Research (A*STAR), Enterprise Singapore (EnterpriseSG), J.P. Morgan, SG Growth Capital, and the Singapore Economic Development Board (EDB) aims to strengthen the region's ability to produce globally scaled medtech leaders and the next generation of global champions.
The opportunity is significant. Asia Pacific’s share of global medtech demand is expected to reach US$132bn by 2030, growing at a compound annual growth rate of 6.9%, ahead of the global rate of 5.5%. Today, the region accounts for about 16%, or US$94bn, of the US$583bn global medical device market, excluding in vitro diagnostics and laboratory equipment.
Healthcare pressures are reshaping medtech demand
The demand story is closely tied to demographic and health system pressures.
Ageing populations are increasing the need for long-term disease management, surgical interventions, rehabilitation, monitoring and home-based care. At the same time, chronic diseases are placing sustained pressure on hospitals, clinics and payers across the region.
Healthcare workforce shortages are adding another layer of urgency. Providers are looking for technologies that help clinicians do more with less, whether through automation, artificial intelligence, digital health platforms, remote monitoring, workflow tools or more efficient diagnostic and therapeutic devices.
This shift is pushing the medtech market toward solutions that demonstrate clear clinical value. Providers and payers are increasingly focused not only on upfront price, but also on measurable outcomes, productivity gains and total cost of care.
That makes Asia Pacific a proving ground for value-based innovation. Technologies designed for constrained environments — where infrastructure is limited, staff are stretched and affordability matters — can become highly relevant in global markets facing similar pressures.
From manufacturing strength to innovation engine
Over the past two decades, Japan and Australia have led Asia Pacific in medtech product development, supported by mature regulatory systems and deep clinical infrastructure. More recently, other markets have begun to move up the innovation ladder.
China and India have moved beyond volume manufacturing and incremental adaptation. South Korea has emerged as a credible engine for software-driven medtech innovation, particularly in artificial intelligence and software as a medical device. Singapore, meanwhile, has strengthened its role as a hub for clinical translation, productisation and advanced manufacturing.
“For a long time, Asia Pacific’s role in medtech was largely defined by manufacturing excellence, adaptation and execution. Now, we are entering a different phase of development,” said Kevin Chang, head of Bain & Company’s Healthcare & Life Sciences practice in Greater China. “The region is no longer simply a market for innovation — it is increasingly becoming a source of it. The next decade will be defined by how effectively companies convert that innovation into enduring global businesses.”
According to the report, Asia Pacific medtech companies are increasingly running global trials, securing regulatory approvals in the US and Europe, publishing clinical data and attracting institutional capital. Rather than simply replicating existing technologies, more companies are developing products with global ambitions from the start.
The region’s research base is also expanding. Its share of global medical device clinical research rose from 29% in 2012 to 36% in 2022, led by China, Japan and India. Asia Pacific also received more than two-thirds of global patent filings in 2023, up from less than 60% a decade earlier.
Regulatory modernisation is shortening the innovation pathway
Governments across Asia Pacific have been redesigning regulatory environments to support medical innovation and accelerate clinical breakthroughs.
In China, the National Medical Products Administration approved 76 innovative medical devices in 2025, a 2.2 times increase over four years. An additional 104 products were admitted to its “Green Channel” fast-track pipeline.
Singapore’s Health Sciences Authority runs a pre-market consultation scheme that allows developers to engage directly with the regulator before formal submission. This helps companies clarify requirements, test their evidence packages early and reduce costly rework. For breakthrough innovations addressing unmet clinical needs in priority healthcare areas, HSA also has a priority review scheme that grants companies 35% shorter turnaround times.
South Korea is also advancing digital medtech regulation. In 2024, the Ministry of Food and Drug Safety designated 29 innovative devices, nearly 80% of which were software-based. Applications increased 137% year over year, reflecting an accelerating software as a medical device pipeline. In January 2025, South Korea’s Digital Medical Products Act became the world’s first standalone law on digital medical products, creating a regulatory pathway for AI diagnostics and SaMD.
These developments are helping the region's medtech companies move faster from concept to validation, and from local approval to global expansion.
Four innovation models emerging across Asia Pacific
The report identifies four broad archetypes shaping medtech innovation in the region, each reflecting different market strengths.
- Japan and Australia are home to “seasoned innovators” built on deep clinical infrastructure and regulatory maturity. Companies in these markets have established track records in global commercialisation and advanced product development.
- China is producing “scale challengers” that compete on speed, breadth and value. These companies have been shaped by a high-volume domestic market, intense price competition and strong manufacturing depth. As margin pressure rises at home, international expansion is becoming increasingly important.
- South Korea is emerging as a centre for “digital-first innovators”, with software and AI at the core of the value proposition. From 2019 to 2023, software-only medtech exports from South Korea grew at a 312% average annual rate. Seoul-based Lunit, for example, has deployed its AI diagnostics system in 10,000 institutions across more than 65 countries.
- India is producing “access-led innovators” that design for constrained environments, where affordability, stretched workforces and infrastructure limitations are central considerations. India’s medical device exports reached US$4bn in FY2025, while companies such as Poly Medicure and Wipro GE have demonstrated the global potential of access-led design.
Together, these models show that Asia Pacific medtech innovation is not developing in a single direction. Instead, some companies are pursuing breakthrough technologies for mature markets, while others are building affordable, scalable solutions for high-volume healthcare systems.
Two routes to global scale
Two main pathways were highlighted for Asia Pacific-originated medtech companies seeking global expansion:
- The first is a global, evidence-led pathway, where companies design products to meet the standards of mature markets from the beginning. This approach requires strong clinical evidence, international trials and early regulatory validation in markets such as the US and Europe.
- The second is a local-first, access-led pathway, where companies build products for local market conditions such as cost constraints, infrastructure gaps and high patient volumes. These products can later scale globally as simpler, more accessible or lower-cost alternatives.
Structural gaps still limit global scale
Despite the momentum, the report notes that relatively few Asia Pacific-originated medtech companies have launched globally competitive, commercially viable products at scale.
Five structural gaps continue to hold companies back:
- The first is funding. Capital remains concentrated at either end of the spectrum. According to venture data from 2025, Seed and Series A rounds totalled only US$2.2bn across 124 rounds, while just 10%, or US$2.3bn, of Asia Pacific buyout value was attributed to medtech deals. Much of this funding went to large, already-scaled platforms rather than emerging companies trying to move from innovation to commercial scale.
- The second is a shortage of regulatory and clinical talent. To launch globally, companies need professionals experienced in FDA submissions, international clinical trials, quality systems and health economics. This expertise remains scarce across much of the region.
- The third is intellectual property protection. Delayed global filing strategies and gaps in patent coverage can constrain licensing, partnership and acquisition opportunities, particularly in the US, Europe and Japan.
- The fourth is commercial infrastructure. Many emerging companies have not yet built the market-entry support, channel networks, key opinion leader relationships and commercial capabilities needed to compete beyond their home markets.
- The fifth is reimbursement and evidence. Regulatory approval is only the beginning of the commercial challenge. Companies increasingly need clinical and health-economic evidence to support adoption, reimbursement and revenue generation.
Singapore’s role in scaling medtech innovation
As Asia Pacific’s medtech ecosystem matures, Singapore is positioning itself as a hub where companies can translate research into globally investible technologies, productise innovations and scale them for international markets.
Singapore’s strengths include regulatory credibility, clinical translation infrastructure, precision engineering capabilities, research networks and an established medtech manufacturing base.
Cindy Koh, Executive Vice President, Advanced Manufacturing, at EDB, said leading medtech companies have anchored significant commercial, manufacturing and R&D activities in Singapore.
“Leading medtech companies have anchored significant commercial, manufacturing, and R&D activities in Singapore, supported by an established ecosystem of clinical, regulatory and research partners, a strong talent pool, and a trusted network of local suppliers,” Koh said.
“This positions Singapore as a hub for global medtech multinationals to access innovation arising from Asia Pacific and develop solutions for global markets.”
Toward Asia Pacific’s next medtech wave
The report concludes that Asia Pacific-originated medtech companies have the potential to move beyond local leadership and produce global champions. But doing so will require the region to move beyond manufacturing excellence toward clinical, regulatory and commercial mastery.
The next 24 months will be important. Investments made now in evidence generation, talent, regulatory alignment, reimbursement capabilities and market access infrastructure will help determine the role Asia-Pacific plays in the global medtech landscape by 2030.
With healthcare demand rising, innovation capacity expanding and ecosystems maturing, Asia Pacific is increasingly positioned not only as a major medtech market, but as a source of medical innovation for the world.
share on
